BATMAN Adv. Mesh network emulator

We introduce a new network emulator environment, developed by our research group, called the BAMNE. Our emulator is designed specifically to allow working with BATMAN Adv. mesh protocols. This mesh network emulator facilitates doing tests with BATMAN Adv. protocol and evaluate and debug mesh networks. The emulated wireless equipment runs in virtual machines using VirtualBox, and the wireless links are simulated with Vde-switch. Vde-switch allows simulating impediments in the link transmission like loss of bits, packet loss, delay. To construct the emulation environment, python language was used.X Workshop Arquitectura, Redes y Sistemas Operativos (WARSO)Red de Universidades con Carreras en Informática (RedUNCI

BATMAN Adv. Mesh network emulator

We introduce a new network emulator environment, developed by our research group, called the BAMNE. Our emulator is designed specifically to allow working with BATMAN Adv. mesh protocols. This mesh network emulator facilitates doing tests with BATMAN Adv. protocol and evaluate and debug mesh networks. The emulated wireless equipment runs in virtual machines using VirtualBox, and the wireless links are simulated with Vde-switch. Vde-switch allows simulating impediments in the link transmission like loss of bits, packet loss, delay. To construct the emulation environment, python language was used.X Workshop Arquitectura, Redes y Sistemas Operativos (WARSO)Red de Universidades con Carreras en Informática (RedUNCI

BATMAN Adv. Mesh network emulator

We introduce a new network emulator environment, developed by our research group, called the BAMNE. Our emulator is designed specifically to allow working with BATMAN Adv. mesh protocols. This mesh network emulator facilitates doing tests with BATMAN Adv. protocol and evaluate and debug mesh networks. The emulated wireless equipment runs in virtual machines using VirtualBox, and the wireless links are simulated with Vde-switch. Vde-switch allows simulating impediments in the link transmission like loss of bits, packet loss, delay. To construct the emulation environment, python language was used.X Workshop Arquitectura, Redes y Sistemas Operativos (WARSO)Red de Universidades con Carreras en Informática (RedUNCI

Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer

Looking through the drive through passing under the building to a rear parking lot to another Moss building, "Umbrella"; A reclamation of old warehouses which needed toxic cleanup, with a new building along the old west wall. There are two primary tenants in the building the architect named Stealth; one is Samitaur Constructs on the south end (a construction company affiliated with Moss). The other, Ogilvy & Mather ad agency, occupies the north end including a ground floor performance and meeting area with a new indoor theater stage with steel doors which open to a grass courtyard performance space. This area was created when the contaminated soil was dug out and removed. The building is 28,000 ft2 in area. Source: Eric Owen Moss [firm website]; http://ericowenmoss.com/ (accessed 7/29/2013

Anticancer effects of anti-CD47 immunotherapy in vivo

The treatment of breast cancer largely depends on the utilization of immunogenic chemotherapeutics, which, as a common leitmotif, stimulate the exposure of calreticulin (CALR) on the surface of cancer cells, thereby facilitating their recognition by dendritic cells for the uptake of tumor-associated antigens and subsequent antigen cross-presentation to cytotoxic T cells. Breast cancer cells also express the calreticulin antagonist CD47, which inhibits tumor cell phagocytosis and consequently subverts anticancer immune responses. Here, we treated carcinogen-induced or transplantable mouse models of cancer by a CD47 blocking antibody that was at least as efficient as chemotherapy and that could be favorably combined with the anthracycline mitoxantrone in the context of carcinogen-induced orthotopic breast cancers. Monotherapy by CD47 blockade led to a reduction in tumor growth and an increase in overall survival. Of note, this treatment lead to a moderate depletion of M2 macrophages as well as close-to-complete elimination of regulatory T cells from the tumor bed, suggesting a strong favorable impact of CD47 blockade on the tumor microenvironment

Ernst Cassirer

Il est indéniable que Cassirer fut un grand historien de la philosophie, un historien parmi les philosophes, comme un philosophe parmi les historiens. En revanche, une question reste ouverte : sa monumentale reconstruction de l’histoire de l’esprit à la manière d’une morphologie de la culture est-elle plutôt une variante kantienne du type de philosophie de l’histoire qui connut, après son heure de gloire hégélienne, un brusque effondrement, consécutif au succès de l’historicisme ? Ou faut-il considérer Cassirer comme un tenant « avant la lettre » de l’histoire-problème, débarrassé de l’historicisme ? L’originalité de notre démarche réside dans le choix d’un regard à la fois interne et externe aux études cassirériennes, puisque ce volume regroupe des spécialistes reconnus de Cassirer, ainsi que des lecteurs qui l’abordent à partir d’autres horizons. La connaissance fine de certaines périodes ou de certains auteurs de l’histoire de la philosophie qu’a analysé Cassirer avec brio permet d’évaluer la pertinence de la construction du discours historique qu’il propose, sans succomber à l’admiration devant son impressionnante érudition et son extraordinaire capacité de synthèse. C’est ainsi probablement que peut se renouveler avec fécondité l’analyse du concept d’histoire au sein de sa philosophie des formes symboliques, une des plus marquantes du XXe siècle

Oral administration of Akkermansia muciniphila elevates systemic antiaging and anticancer metabolites

International audienceThe presence of Akkermansia muciniphila (Akk) in the human gut is associated with good health, leanness and fitness. Mouse experimentation has demonstrated positive effects for Akk, which counteracts aging, mediates antiobesity and antidiabetic effects, dampens inflammation and improves anticancer immunosurveillance. Clinical trials have confirmed antidiabetic effects for Akk. Here, we investigated the time-dependent effects of oral administration of Akk (which was live or pasteurized) and other bacteria to mice on the metabolome of the ileum, colon, liver and blood plasma. Metabolomics was performed by a combination of chromatographic and mass spectrometric methods, yielding a total of 1.637.227 measurements. Akk had major effects on metabolism, causing an increase in spermidine and other polyamines in the gut and in the liver. Pasteurized Akk (Akk-past) was more efficient than live Akk in elevating the intestinal concentrations of polyamines, short-chain fatty acids, 2-hydroxybutyrate, as well multiple bile acids, which also increased in the circulation. All these metabolites have previously been associated with human health, providing a biochemical basis for the beneficial effects of Akk

Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity

Systemic treatment with the active transcription inhibitor lurbinectedin aims at inducing tumor cell death in hyperproliferative neoplasms. Here we show that cell death induced by lurbinectedin reinstates and enhances systemic anticancer immune responses. Lurbinectedin treatment showed traits of immunogenic cell death, including the exposure of calreticulin, the release of ATP, the exodus of high mobility group box 1 (HMGB1) and type 1 interferon responses in vitro. Lurbinectedin treated cells induced antitumor immunity when injected into immunocompetent animals and treatment of transplanted fibrosarcomas reduced tumor growth in immunocompetent yet not in immunodeficient hosts. Anticancer effects resulting from lurbinectedin treatment were boosted in combination with PD-1 and CTLA-4 double immune checkpoint blockade (ICB), and lurbinectedin combined with double ICB exhibited strong antineoplastic effects. Cured animals exhibited long term immune memory effects that rendered them resistant to rechallenge with syngeneic tumors underlining the potency of combination therapy with lurbinectedin

Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals

Abstract Oncolytic peptides and peptidomimetics are being optimized for the treatment of cancer by selecting agents with high cytotoxic potential to kill a maximum of tumor cells as well as the capacity to trigger anticancer immune responses and hence to achieve long-term effects beyond therapeutic discontinuation. Here, we report on the characterization of two novel oncolytic peptides, DTT-205 and DTT-304 that both selectively enrich in the lysosomal compartment of cancer cells yet differ to some extent in their cytotoxic mode of action. While DTT-304 can trigger the aggregation of RIP3 in ripoptosomes, coupled to the phosphorylation of MLKL by RIP3, DTT-205 fails to activate RIP3. Accordingly, knockout of either RIP3 or MLKL caused partial resistance against cell killing by DTT-304 but not DTT-205. In contrast, both agents shared common features in other aspects of pro-death signaling in the sense that their cytotoxic effects were strongly inhibited by both serum and antioxidants, partially reduced by lysosomal inhibition with bafilomycin A1 or double knockout of Bax and Bak, yet totally refractory to caspase inhibition. Both DTT-304 and DTT-205 caused the exposure of calreticulin at the cell surface, as well as the release of HMGB1 from the cells. Mice bearing established subcutaneous cancers could be cured by local injection of DTT-205 or DTT-304, and this effect depended on T lymphocytes, as it led to the establishment of a long-term memory response against tumor-associated antigens. Thus, mice that had been cured from cancer by the administration of DTT compounds were refractory against rechallenge with the same cancer type several months after the disappearance of the primary lesion. In summary, DTT-205 and DTT-304 both have the capacity to induce immunotherapeutic oncolysi